Trial reportGut2000
Faecal calprotectin levels in a high risk population for colorectal neoplasia.
Trial report in Gut, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis.BMC gastroenterology · 2022Pooled it
- Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Pooled it
- A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation.British journal of cancer · 2005Trial
- Trial
- Factors Associated With Loss of Fecal Biomarker Accuracy During Routine Assessment of Inflammatory Bowel Disease.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Research progress on the diagnostic value of fecal calprotectin in colorectal tumors.Frontiers in medicine · 2025Review
- Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy.International journal of colorectal disease · 2022Article
- Increase of Neutrophil Activation Markers in Venous Thrombosis-Contribution of Circulating Activated Protein C.International journal of molecular sciences · 2020Article
- Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.World journal of gastroenterology · 2014Article
- A predictive model combining fecal calgranulin B and fecal occult blood tests can improve the diagnosis of colorectal cancer.PloS one · 2014Article
- A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.International journal of colorectal disease · 2011Article
- Local calprotectin production in colorectal cancer and polyps--active neutrophil recruitment in carcinogenesis.International journal of colorectal disease · 2011Article
- Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.International journal of colorectal disease · 2008Article
- Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.International journal of colorectal disease · 2007Article
- Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests?World journal of gastroenterology · 2007Review
- Physical activity before and after diagnosis of colorectal cancer: disease risk, clinical outcomes, response pathways and biomarkers.Sports medicine (Auckland, N.Z.) · 2007Review
- Plasma calprotectin levels in patients suffering from acute pancreatitis.Digestive diseases and sciences · 2006Article
- Biomarkers of Inflammation and Immune Function and Risk of Colorectal Cancer.Current colorectal cancer reportsReview
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaecal concentrations of the protein calprotectin have been found to be elevated in patients with colorectal neoplasia, suggesting that it might be used as a screening tool for colorectal cancer as well as adenomas.
aimsTo measure the sensitivity and specificity of faecal calprotectin for the detection of adenomas in high risk individuals undergoing colonoscopy. Also, to investigate between and within stool variability of calprotectin concentrations. SUBJECTS: A total of 814 patients planned for colonoscopy were included for the following indications: positive faecal occult blood test, 25; neoplasia surveillance, 605; newly detected polyp, 130; and family risk, 54.
methodsTwo faecal samples from each of two stools were analysed using the PhiCal ELISA test device (Nycomed Pharma AS).
resultsAdenoma patients had significantly higher calprotectin levels than normal subjects (median 9.1 (95% confidence interval 7.5-10.1) v 6.6 (5.6-7.4)mg/l). There was no significant decrease in calprotectin levels after polypectomy. Levels in cancer patients were significantly higher than those in all other subgroups (median 17.6 mg/l (11.5-31.0)). With a cut off limit of 10 mg/l, the sensitivity for cancer was 74% and for adenoma 43%. Corresponding specificity values were 64% for no cancer and 67% for no neoplasia (cancer+adenoma). Specificity varied from 71% for one stool sample to 63% for four samples. Stool variability was small, suggesting that two spots from one stool were as discriminative as two spots from each of two stools.
conclusionsThe sensitivity and specificity of faecal calprotectin levels as a marker for colorectal adenoma and carcinoma justifies its use in high risk groups, but specificity is too low for screening of average risk persons. Lack of a decrease in levels after polypectomy may be due to a more widespread leucocyte migration into the intestinal lumen than that at the polyp site, and needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.